FARGO, N.D., Nov. 07, 2025 (GLOBE NEWSWIRE) — NI Holdings, Inc. (NASDAQ: NODK) announced today results for the quarter ended September 30, 2025. Summary of Third Quarter 2025 Results – Continuing Operations(All comparisons vs. continuing operations for the third quarter of 2024, unless noted otherwise)Direct written premiums of $58.5 million compared to $67.7 million in the prior period. The decrease was primarily driven by an 80.0% decline in Non-Standard Auto, reflecting the Company’s strategic decision during the quarter to stop writing this business in Illinois, Arizona and South Dakota. This decline was partially offset by a 10.1% increase in Home and Farm premiums, driven by new business growth in North Dakota, rate increases, and increased insured property values, partially offset by lower retention and new business in...

Enhancing and Expanding our ETF Product Offerings Quarter End AUM of $35.0 billion (+9% versus Q3 2024) Quarterly Revenues Grew 10% to $63.2 million Third Quarter EPS of $0.68 versus $0.69 in the Third Quarter of 2024 Strong Liquidity Position and Cash Generation Support Capital Returns: $200.8 million in Cash and Investments (No Debt); 22.1 million Shares Outstanding After Repurchasing 237,000 Shares During Q3 2025 Board Authorizes 25% Increase to Quarterly Dividend to $0.10 Per Share, an Additional 500,000 Share Buyback, and $2.5 million Charitable Contribution Chairman and co-CEO Elects to Waive Management Fee for DecemberGREENWICH, Conn., Nov. 07, 2025 (GLOBE NEWSWIRE) — GAMCO Investors, Inc. (“Gabelli”) (OTCQX: GAMI) today reported its operating results for the quarter ended September 30, 2025. Please use this link to see...

IRVINE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) — Cheetah Net Supply Chain Service Inc. (“Cheetah” or the “Company”) (Nasdaq CM: CTNT), a provider of warehousing and logistics services, today reported results for the quarter ended September 30, 2025. For the quarter ended September 30, 2025, the Company reported revenue of $361,935 from its logistics and warehousing business, representing a 491.3% increase compared to the same period in 2024. The operating loss was $1,314,650, including impairment loss of $731,307 on intangible assets and goodwill. After accounting for interest income of $269,927, the Company reported a net loss of $1,314,650, representing a 15.0% decrease compared to the same period in 2024. Tony Liu, Cheetah’s Chairman and CEO commented, “During the third quarter, our business continued to face challenges from...

CARLSBAD, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) — Viasat, Inc. (NASDAQ: VSAT), a global leader in satellite communications, today published its second quarter fiscal year 2026 financial results in a letter to shareholders, which, along with webcast slides, is now posted to the Investor Relations section of Viasat’s website. As previously announced, Viasat will host a conference call today, Friday, November 7, 2025 at 2:30 p.m. Pacific Time / 5:30 p.m. Eastern Time. To participate on the live conference call, please dial (800) 715-9871 toll-free in the U.S. or Internationally, or (646) 307-1963 in the U.S., and reference the conference ID 2291081. Participants can also listen to the live webcast from the Investor Relations section of the Viasat website. The call will be archived and available on the site for approximately one month...

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) — Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a business update. Business HighlightsSurrozen remains focused on its ophthalmology pipeline, leveraging its Wnt biology expertise and antibody technologies to develop novel treatments for severe eye diseases. Key Third Quarter Events and Planned Fourth Quarter Scientific Meetings in 2025Ophthalmology Pipeline:The Company continues to progress its lead candidates, SZN-8141 and SZN-8143 in retinal diseases and remains on track to submit an Investigational...

— Zola® year-to-date revenues increase 26% year over year —— Arcadia gross profit margins exceed 30% for 11th straight quarter —— Arcadia cash balance declines by only $257K to $1.1M — DALLAS, Nov. 07, 2025 (GLOBE NEWSWIRE) — Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, today released its financial and business results for the third quarter of 2025. “We are very pleased with our performance for the third quarter of 2025.” said T.J. Schaefer, CEO of Arcadia. “Zola® coconut water revenues were flat year-over-year in the third quarter as we overlapped the initial sell-in to Zola’s largest customer during the third quarter of 2024. However, on a year-to-date basis, Zola coconut water revenues have grown 26% and more than offset $700,000 in GLA...

MONTREAL, Nov. 07, 2025 (GLOBE NEWSWIRE) — Senvest Capital Inc. today reported net income attributable to common shareholders of $172.8 million or $70.98 per share for the three months ended September 30, 2025. This compares to a net income attributable to common shareholders of $170.5 million or 69.24 per share for the same period in 2024 Financial statements are available online at Sedar+ www.sedarplus.ca  CONSOLIDATED STATEMENTS OF INCOME  (unaudited)  (in millions of dollars, except per share amounts)  For the three months ended         09/30/2025   09/30/2024       Net income attributable tocommon shareholders $172.8   $170.5       Diluted earnings per share attributable to common shareholders $70.98   $69.24Contact:George Malikotsis, Vice President Finance(514) 281-8082

JIANGYIN, China, Nov. 07, 2025 (GLOBE NEWSWIRE) — Li Bang International Corporation Inc. (“Li Bang International”) and its subsidiaries (collectively, the “Company,” “we,” “us,” “our company,” or “Li Bang”) (Nasdaq: LBGJ), a company engaged in designing, developing, producing, and selling stainless steel commercial kitchen equipment in China, today announced its audited financial results for the fiscal year ended June 30, 2025. Highlights for Fiscal Year Ended June 30, 2025Total revenue increased 2.9% to approximately $11.1 million for the year ended June 30, 2025 from approximately $10.8 million for fiscal year 2024. Gross profit increased 4.1% to approximately $3.2 million for the year ended June 30, 2025, compared to approximately $2.7 million for fiscal...

Management Board of Baltic Horizon Capital AS (previously Northern Horizon Capital AS) has approved the unaudited financial results of Baltic Horizon Fund (the Fund) for the nine months of 2025. The Fund reports on its 9 months of operations in 2025 under the new composition of its management board as well as the new ownership of its management company which are effective from 30 October 2025. In connection with this change of ownership, the management company has changed its name to Baltic Horizon Capital AS. The management estimates that approximately EUR 25 million in new equity is required to enable full repayment of the bonds and funding asset enhancement projects on the current portfolio. Over the course of November, the management will communicate to the market the terms of the new units offering which will be intended for the existing...

— New preclinical data for PM577 in Wilson’s Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1’26, with initial clinical data expected in 2027 —  — Nominated PM647 as development candidate for Alpha-1 Antitrypsin Deficiency (AATD); on-track to file IND and/or CTA in mid-2026, with initial clinical data expected in 2027 — — Strengthened leadership team with the appointment of Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer — — Company to host virtual KOL event at 8:00am ET on Wednesday, November 12, 2025 to showcase Wilson’s Disease Strategy — CAMBRIDGE, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) — In a release issued earlier today by Prime Medicine, Inc. (Nasdaq: PRME) under the same headline, please note the first paragraph under “Prime Medicine’s...